Selected research
Industry Research
Anemia Drugs Industry Research Report 2026
Market perspective
The global Anemia Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anemia Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anemia Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anemia Drugs include Eli Lilly, GlaxoSmithKline, Bayer AG, Regen Biopharma, Pieris Pharmaceuticals, Onconova Therapeutics, Mast Therapeutics, GlycoMimetics and Global Blood Therapeutics (GBT), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anemia Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anemia Drugs Market by Company
Eli Lilly
GlaxoSmithKline
Bayer AG
Regen Biopharma
Pieris Pharmaceuticals
Onconova Therapeutics
Mast Therapeutics
GlycoMimetics
Global Blood Therapeutics (GBT)
Fibrogen
Celgene Corporation
Bluebird Bio
Akebia Therapeutics
Acceleron Pharma
Anemia Drugs Segment by Type
Oral
Injection
Anemia Drugs Segment by Application
Aplastic Anemia
Iron Deficiency Anemia
Chronic Kidney Disease related Anemia
Sickle Cell Anemia
Anemia Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anemia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anemia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anemia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anemia Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anemia Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anemia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Aplastic Anemia
- Iron Deficiency Anemia
- Chronic Kidney Disease related Anemia
- Sickle Cell Anemia
Companies covered
- Eli Lilly
- GlaxoSmithKline
- Bayer AG
- Regen Biopharma
- Pieris Pharmaceuticals
- Onconova Therapeutics
- Mast Therapeutics
- GlycoMimetics
- Global Blood Therapeutics (GBT)
- Fibrogen
- Celgene Corporation
- Bluebird Bio
- Akebia Therapeutics
- Acceleron Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anemia Drugs Market Size (2021-2032)
- 2.2.2 Global Anemia Drugs Sales (2021-2032)
- 2.2.3 Global Anemia Drugs Market Average Price (2021-2032)
- 2.3 Anemia Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Injection
- 2.4 Anemia Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Aplastic Anemia
- 2.4.3 Iron Deficiency Anemia
- 2.4.4 Chronic Kidney Disease related Anemia
- 2.4.5 Sickle Cell Anemia
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anemia Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anemia Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Anemia Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Anemia Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Anemia Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anemia Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anemia Drugs, Product Type & Application
- 3.8 Global Manufacturers of Anemia Drugs, Established Date
- 3.9 Global Anemia Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eli Lilly
- 4.1.1 Eli Lilly Company Information
- 4.1.2 Eli Lilly Business Overview
- 4.1.3 Eli Lilly Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eli Lilly Anemia Drugs Product Portfolio
- 4.1.5 Eli Lilly Recent Developments
- 4.2 GlaxoSmithKline
- 4.2.1 GlaxoSmithKline Company Information
- 4.2.2 GlaxoSmithKline Business Overview
- 4.2.3 GlaxoSmithKline Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Anemia Drugs Product Portfolio
- 4.2.5 GlaxoSmithKline Recent Developments
- 4.3 Bayer AG
- 4.3.1 Bayer AG Company Information
- 4.3.2 Bayer AG Business Overview
- 4.3.3 Bayer AG Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer AG Anemia Drugs Product Portfolio
- 4.3.5 Bayer AG Recent Developments
- 4.4 Regen Biopharma
- 4.4.1 Regen Biopharma Company Information
- 4.4.2 Regen Biopharma Business Overview
- 4.4.3 Regen Biopharma Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Regen Biopharma Anemia Drugs Product Portfolio
- 4.4.5 Regen Biopharma Recent Developments
- 4.5 Pieris Pharmaceuticals
- 4.5.1 Pieris Pharmaceuticals Company Information
- 4.5.2 Pieris Pharmaceuticals Business Overview
- 4.5.3 Pieris Pharmaceuticals Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pieris Pharmaceuticals Anemia Drugs Product Portfolio
- 4.5.5 Pieris Pharmaceuticals Recent Developments
- 4.6 Onconova Therapeutics
- 4.6.1 Onconova Therapeutics Company Information
- 4.6.2 Onconova Therapeutics Business Overview
- 4.6.3 Onconova Therapeutics Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Onconova Therapeutics Anemia Drugs Product Portfolio
- 4.6.5 Onconova Therapeutics Recent Developments
- 4.7 Mast Therapeutics
- 4.7.1 Mast Therapeutics Company Information
- 4.7.2 Mast Therapeutics Business Overview
- 4.7.3 Mast Therapeutics Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mast Therapeutics Anemia Drugs Product Portfolio
- 4.7.5 Mast Therapeutics Recent Developments
- 4.8 GlycoMimetics
- 4.8.1 GlycoMimetics Company Information
- 4.8.2 GlycoMimetics Business Overview
- 4.8.3 GlycoMimetics Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GlycoMimetics Anemia Drugs Product Portfolio
- 4.8.5 GlycoMimetics Recent Developments
- 4.9 Global Blood Therapeutics (GBT)
- 4.9.1 Global Blood Therapeutics (GBT) Company Information
- 4.9.2 Global Blood Therapeutics (GBT) Business Overview
- 4.9.3 Global Blood Therapeutics (GBT) Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Global Blood Therapeutics (GBT) Anemia Drugs Product Portfolio
- 4.9.5 Global Blood Therapeutics (GBT) Recent Developments
- 4.10 Fibrogen
- 4.10.1 Fibrogen Company Information
- 4.10.2 Fibrogen Business Overview
- 4.10.3 Fibrogen Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Fibrogen Anemia Drugs Product Portfolio
- 4.10.5 Fibrogen Recent Developments
- 4.11 Celgene Corporation
- 4.11.1 Celgene Corporation Company Information
- 4.11.2 Celgene Corporation Business Overview
- 4.11.3 Celgene Corporation Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Celgene Corporation Anemia Drugs Product Portfolio
- 4.11.5 Celgene Corporation Recent Developments
- 4.12 Bluebird Bio
- 4.12.1 Bluebird Bio Company Information
- 4.12.2 Bluebird Bio Business Overview
- 4.12.3 Bluebird Bio Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Bluebird Bio Anemia Drugs Product Portfolio
- 4.12.5 Bluebird Bio Recent Developments
- 4.13 Akebia Therapeutics
- 4.13.1 Akebia Therapeutics Company Information
- 4.13.2 Akebia Therapeutics Business Overview
- 4.13.3 Akebia Therapeutics Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Akebia Therapeutics Anemia Drugs Product Portfolio
- 4.13.5 Akebia Therapeutics Recent Developments
- 4.14 Acceleron Pharma
- 4.14.1 Acceleron Pharma Company Information
- 4.14.2 Acceleron Pharma Business Overview
- 4.14.3 Acceleron Pharma Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Acceleron Pharma Anemia Drugs Product Portfolio
- 4.14.5 Acceleron Pharma Recent Developments
5 Global Anemia Drugs Market Scenario by Region
- 5.1 Global Anemia Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anemia Drugs Sales by Region: 2021-2032
- 5.2.1 Global Anemia Drugs Sales by Region: 2021-2026
- 5.2.2 Global Anemia Drugs Sales by Region: 2027-2032
- 5.3 Global Anemia Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Anemia Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Anemia Drugs Revenue by Region: 2027-2032
- 5.4 North America Anemia Drugs Market Facts & Figures by Country
- 5.4.1 North America Anemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anemia Drugs Sales by Country (2021-2032)
- 5.4.3 North America Anemia Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Anemia Drugs Market Facts & Figures by Country
- 5.5.1 Europe Anemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anemia Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Anemia Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Anemia Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anemia Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anemia Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anemia Drugs Market Facts & Figures by Country
- 5.7.1 South America Anemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anemia Drugs Sales by Country (2021-2032)
- 5.7.3 South America Anemia Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Anemia Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anemia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anemia Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anemia Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Anemia Drugs Sales by Type (2021-2032)
- 6.1.1 Global Anemia Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Anemia Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Anemia Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Anemia Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anemia Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Anemia Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anemia Drugs Sales by Application (2021-2032)
- 7.1.1 Global Anemia Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Anemia Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Anemia Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Anemia Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anemia Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Anemia Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anemia Drugs Value Chain Analysis
- 8.1.1 Anemia Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anemia Drugs Production Mode & Process
- 8.2 Anemia Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anemia Drugs Distributors
- 8.2.3 Anemia Drugs Customers
9 Global Anemia Drugs Analyzing Market Dynamics
- 9.1 Anemia Drugs Industry Trends
- 9.2 Anemia Drugs Industry Drivers
- 9.3 Anemia Drugs Industry Opportunities and Challenges
- 9.4 Anemia Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst